FDA sends 30 warning letters to telehealth firms over compounded GLP-1 ads

The Food and Drug Administration announced on March 3, 2026 that it sent 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products offered on their websites ^[1]. It is the second group of warning letters sent to telehealth firms since the agency began a crackdown on misleading direct-to-consumer drug advertising in September 2025, according to a compliance alert from the law firm Frier Levitt ^[1].

FDA Commissioner Marty Makary said, "It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action." ^[1] The FDA also stated that over the six months before the announcement, thousands of warning letters had been sent to pharmaceutical and telehealth firms over misleading ads, more than in the entire preceding decade ^[1].

What drew the letters

The alert says enforcement turned on how compounded products were described, not on compounding itself. The FDA cited telehealth companies for claims implying their compounded products were generic equivalents of branded drugs, or had been tested in clinical trials ^[1]. Compounded drug products are not FDA-approved, and the FDA does not review their safety or effectiveness ^[1].

A second issue was sourcing. In several letters, the FDA objected to advertising for compounded products that appeared to carry the telehealth firm's own name or trademark, which suggests the telehealth company prepared the medication ^[1].

Companies that received letters must explain in writing how they plan to fix the cited violations and prevent them from happening again. The FDA asked recipients to identify the entities that produced the compounded products, provide a sample of the products' labeling, remove safety and efficacy claims, and address other website claims that could be seen as false or misleading ^[1]. Recipients have 15 days to respond. If the FDA does not receive a timely answer, the agency said, companies may face "legal action without further notice, including, without limitation, seizure and injunction" ^[1].

Beyond federal rules, the alert says marketing that implies a telehealth company made the drug can create the impression that the company is practicing pharmacy without a license under state Pharmacy Practice Acts ^[1]. It advises companies to keep administrative, prescribing and compounding functions clearly separated and to review website content and marketing materials against current FDA guidance ^[1].

This is not the first round. On December 17, 2024, the FDA issued warning letters to five companies offering GLP-1 products including semaglutide, tirzepatide, retatrutide, cagrilintide, mazdutide, survodutide and sermorelin, after reviewing therapeutic claims on websites and social media, and called the products unapproved new drugs ^[2]. Some of those products were labeled "for research use only and not for human consumption or clinical use," but the FDA said website and social media content showed they were intended for human use, and one letter cited claims that products were FDA-approved as misbranding ^[2]. Those companies had 15 business days to respond; the 2026 letters described in the compliance alert give recipients 15 days ^[1][2].

Why it matters for patients

The letters target advertising claims, not the act of compounding, so the alert does not say that compounded GLP-1 products are being removed from the market ^[1]. What it does describe is a gap patients may not see: compounded drugs are not FDA-approved and the agency does not review their safety or effectiveness, so statements that a compounded product is equivalent to a brand-name medicine, or has been tested in trials, are the kind of claim now drawing enforcement ^[1].

For someone comparing a compounded product with a brand-name medicine such as Ozempic or Wegovy (semaglutide) or Mounjaro or Zepbound (tirzepatide), the practical effect is that advertising and websites may change, and some claims may disappear. Whether these letters lead to shortages of compounded products, changes in pricing or changes in which telehealth services remain available has not been reported.

The names of the 30 companies have not been disclosed. It also has not been reported how many of the 30 have responded to the FDA or what those responses said. Separately, the earlier letters were issued to companies that sold products for "research use only," a category the FDA said was intended for human use based on their marketing ^[2].

What happens next

The 30 companies have 15 days to respond in writing to the FDA, explaining the steps they have taken to correct the violations and prevent repeats ^[1]. If the agency does not receive a timely response, it said legal action may follow, including seizure and injunction ^[1]. The FDA has not said whether additional warning letters to telehealth companies are planned, and it has not been reported whether any of the 30 letters have been resolved ^[1].